SCHEMBL24312784

SCHEMBL24312784

COC(=O)C1CCN(c2ccc(Br)cn2)CC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.60
KMT2A Q03164 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
MEN1 O00255 2/20 0.59
ALDH1A1 P00352 2/20 0.51
HTT P42858 1/20 0.51
LMNA P02545 2/20 0.49
AKR1C3 P42330 1/20 0.49
PANK3 Q9H999 1/20 0.47
ADORA3 P0DMS8 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
MAPT P10636 1/20 0.46
ABL1 P00519 1/20 0.45
ACACB O00763 1/20 0.44
TP53 P04637 1/20 0.43
USP30 Q70CQ3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592865 1.00 KDM4E (0.60) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL20474651 0.86 ACACB (0.51) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL30473867 0.86 ACACB (0.51) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL374689 0.86 USP30 (0.55) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL30201729 0.86 KMT2A (0.48) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL25074367 0.86 KMT2A (0.48) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL10174357 0.85 KDM4E (0.61) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL18248410 0.84 KDM4E (0.60) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL15205885 0.83 LMNA (0.55) KDM4EKMT2AHTTLMNAAKR1C3
SCHEMBL24837942 0.82 KDM4E (0.65) KDM4EKMT2ASMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246961-A1 AUTOTAXIN INHIBITOR COMPOUNDS ILDONG PHARMACEUTICAL CO., LTD. (KR) 2024-07-25 US disclosed
US-20240174674-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) 2024-05-30 US disclosed
US-11970493-B2 Autotaxin inhibitor compounds ILDONG PHARMACEUTICAL CO., LTD. (KR) 2024-04-30 US disclosed
CN-114907338-B Nitrogen-containing polycyclic condensed ring compound, pharmaceutical composition, preparation method and application thereof 北京志健金瑞生物医药科技有限公司 2024-02-06 CN disclosed
EP-4289428-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF Applied Pharmaceutical Science, Inc. (CN) 2023-12-13 EP disclosed
EP-4289428-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF Applied Pharmaceutical Science, Inc. (CN) 2023-12-13 EP disclosed
EP-4225756-A2 AUTOTAXIN INHIBITOR COMPOUNDS Ildong Pharmaceutical Co., Ltd. (KR) 2023-08-16 EP disclosed
CN-116322692-A Autotaxin inhibitor compounds 日东制药株式会社 2023-06-23 CN disclosed
CN-114907338-A Nitrogen-containing polycyclic fused ring compound, and pharmaceutical composition, preparation method and application thereof 北京志健金瑞生物医药科技有限公司 2022-08-16 CN disclosed
WO-2022166642-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF 北京志健金瑞生物医药科技有限公司 2022-08-11 WO disclosed
WO-2022074459-A2 AUTOTAXIN INHIBITOR COMPOUNDS ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-04-14 WO disclosed
WO-2022074459-A2 AUTOTAXIN INHIBITOR COMPOUNDS ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-04-14 WO disclosed
US-20220106311-A1 AUTOTAXIN INHIBITOR COMPOUNDS ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246961-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, ATXN10, ATXN2L KDM4E 1416/4885KMT2A 743/4885SMN1; SMN2 588/4885
US-20220106311-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, ATXN10, ATXN2L KDM4E 1416/4885KMT2A 743/4885SMN1; SMN2 588/4885
US-11970493-B2 Autotaxin inhibitor compounds ENPP2, ATXN10, ATXN2L KDM4E 1416/4885KMT2A 743/4885SMN1; SMN2 588/4885
US-20240174674-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF RET, WEE1, JAK2 KDM4E 2644/4885KMT2A 2971/4885SMN1; SMN2 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.